For decades, the dream of rewriting disease at the genetic level has been constrained not by imagination but by geometry — the tools precise enough to activate specific genes have been too large to travel safely through the body. Stanford Medicine researchers have now introduced TIGRa, a gene activation system less than half the size of CRISPR-based tools, compact enough to be carried inside viral vectors with room to spare. In mouse models of retinal injury, TIGRa preserved roughly a third of vision that would otherwise have been lost — a quiet but significant proof that the physical barriers